Showing 8461-8470 of 10255 results for "".
- Elevator Pitch Sessions Launching from The Medical Entrepreneurhttps://practicaldermatology.com/news/20130924-elevator_pitch_sessions_launching__from_the_medical_entrepreneur/2459454/The Medical Entrepreneur Symposium is introducing a one day event on Saturday December 7 in Delray Beach. The “Elevator Pitch Sessions” will be geared towards helping physicians learn how to fund their next venture. "We are excite
- FDA Approves Mirvaso for Treating Facial Erythema of Rosaceahttps://practicaldermatology.com/news/20130826-fda_approves_mirvaso_for_treating_facial_erythema_of_rosacea/2459476/The FDA recently approved Mirvaso (brimonidine) gel, 0.33% for the topical treatment of the facial erythema of rosacea in adults 18 years of age or older. According to manufacturer Galderma Laboratories, applied once
- Live Cosmetic Surgery Workshop This Septemberhttps://practicaldermatology.com/news/20130812-live_cosmetic_surgery_workshop_this_september/2459480/Dr. Joe Niamtu, III will present the 2013 Ultimate Facial Rejuvenation Live Cosmetic Surgery Workshop September 20-22. The course will include lectures and live surgeries on:facelift and facial liposuction, browlift, eyelid surgery, facial implants, laser resurfacing, chemical peels, fillers, mole r
- LEO Launches Taclonex in Larger Package Sizehttps://practicaldermatology.com/news/20130730-leo_launches_taclonex_in_larger_package_size/2459488/LEO Pharma Inc., has launched a patient-friendly 120g package size of Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of plaque psoriasis.
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with
- Geneticists Research Cleft Palate and Skin Deformitieshttps://practicaldermatology.com/news/20130614-geneticists_research_cleft_palate_and_skin_deformities/2459514/Scientists at Cold Spring Harbor Laboratory (CSHL) solved the mystery of why some infants are born with cleft palate and major deformities of the skin and limbs, while other infants with the same genetic mutation bear little or no sign of the illness, called Ectodactyly, Ectodermal dysplasia, Clefti
- Skin Health Seminars to Begin Next Monthhttps://practicaldermatology.com/news/20130522-skin_health_seminars_to_begin_next_month/2459532/ZO Skin Health, Inc. will host a series of educational seminars and webinars on “Expanded Concepts and Principles of Skin Health Science,” created and presented by Zein Obagi, MD, and board-certified dermatologist Monika Kiripolsky, MD. Each seminar plans to educate skincare professionals and cons
- Anterios CEO to Present at Healthcare Conferencehttps://practicaldermatology.com/news/20130429-anterios_ceo_to_present_at_healthcare_conference/2459558/CEO and Founder of Anterios, Inc., Jon Edelson, MD, will be presenting at Needham & Company's 12th Annual Healthcare Conference in New York City on April 30, 2013. In other company news, Anterios also recently received an $8.5 million round of
- HydraSolve Cleared for Autologous Fat Transferhttps://practicaldermatology.com/news/20130425-hydrasolve_cleared_for_autologous_fat_transfer/2459559/The new Hydrasolve liposuction device has recently been FDA-cleared for autologous fat transfer, a first-of-its-kind indication in the liposuction realm. The new clearance enables clinicians to harvest and re-inject fat from the initial HydraSolve liposuction procedure for rejuvenations or augmentat
- OPTiM Trial Results: New Immunotherapy Study in Melanomahttps://practicaldermatology.com/news/20130409-optim_trial_results_new_immunotherapy_study_in_melanoma/2459569/Results from the Oncovex (GM-CSF) Pivotal Trial in Melanoma (OPTiM) show that a genetically modified version of herpes simplex virus type 1, designated talimogene laherparepvec (T-VEC), shrank melanoma in patients who were in the late stages of the disease. The T-VEC virus works through direct dest